114 related articles for article (PubMed ID: 6998553)
1. High-dose methotrexate with "RESCUE" plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence of C parvum immunotherapy.
Barlow JJ; Piver MS; Lele SB
Cancer; 1980 Sep; 46(6):1333-8. PubMed ID: 6998553
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Barlow JJ; Lele SB; Emrich LJ
Am J Obstet Gynecol; 1985 Jun; 152(3):310-4. PubMed ID: 2988337
[TBL] [Abstract][Full Text] [Related]
4. Cis-platin-Mecy as salvage chemotherapy in recurrent advanced ovarian carcinoma.
Belli M; Colantuoni G; Di Iorio B
G Ital Oncol; 1989; 9(1):31-3. PubMed ID: 2785083
[TBL] [Abstract][Full Text] [Related]
5. Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
Piver MS; Barlow JJ; Bhattacharya M
Cancer Treat Rep; 1979 Feb; 63(2):265-7. PubMed ID: 376133
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer.
Barlow JJ; Piver MS
Cancer Treat Rep; 1976 May; 60(5):527-33. PubMed ID: 1086714
[TBL] [Abstract][Full Text] [Related]
8. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer.
DeConti RC; Schoenfeld D
Cancer; 1981 Sep; 48(5):1061-72. PubMed ID: 7023649
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced ovarian malignancy with chemoimmunotherapy using autologous tumor and Corynebacterium parvum.
Gusdon JP; Homesley HD; Jobson VW; Muss HB
Obstet Gynecol; 1983 Dec; 62(6):728-35. PubMed ID: 6633998
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of studies of the effect of immunostimulation combined with chemotherapy in patients with ovarian cancer].
Pawlicki M; Majsak T
Ginekol Pol; 1988 Jun; 59(6):358-62. PubMed ID: 3069616
[No Abstract] [Full Text] [Related]
12. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Smalley RV; Vogler WR
Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
[TBL] [Abstract][Full Text] [Related]
13. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT
N Engl J Med; 1978 Dec; 299(23):1261-6. PubMed ID: 101843
[TBL] [Abstract][Full Text] [Related]
14. Combination chemoimmunotherapy for extensive non-oat cell lung cancer.
Issell BF; Valdivieso M; Hersh EM; Richman S; Gutterman JU; Bodey GP
Cancer Treat Rep; 1978 Jul; 62(7):1059-63. PubMed ID: 356968
[TBL] [Abstract][Full Text] [Related]
15. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
[TBL] [Abstract][Full Text] [Related]
16. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW
Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: a randomized study comparing different times and routes of administration of Corynebacterium parvum.
Fritze D; Massner B; Becher R; Kaufmann M; Illiger HJ; Hartlapp J; Queisser W; Abel U; Edler L; Mayr AC
Klin Wochenschr; 1984 Feb; 62(4):162-7. PubMed ID: 6368960
[TBL] [Abstract][Full Text] [Related]
18. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
Henderson IC; Gelman R; Canellos GP; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.
Fisher B; Wolmark N; Saffer E; Fisher ER
Cancer; 1975 Jan; 35(1):134-43. PubMed ID: 1109767
[TBL] [Abstract][Full Text] [Related]
20. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
Purnell DM; Bartlett GL; Kreider JW; Biro TG
Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
